List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6065014/publications.pdf Version: 2024-02-01



ADDIL COAN

#	Article	IF	CITATIONS
1	Cytoneme delivery of Sonic Hedgehog from ligand-producing cells requires Myosin 10 and a Dispatched-BOC/CDON co-receptor complex. ELife, 2021, 10, .	6.0	45
2	SLFN11 is Widely Expressed in Pediatric Sarcoma and Induces Variable Sensitization to Replicative Stress Caused By DNA-Damaging Agents. Molecular Cancer Therapeutics, 2021, 20, 2151-2165.	4.1	6
3	The impact of tumor excision on American Society of Anesthesiologyâ€Physical Status scoring among pediatric anesthesiologists: A retrospective review. Paediatric Anaesthesia, 2021, 31, 491-493.	1.1	0
4	Chemoreduction with topotecan and vincristine: Quantifying tumor response in bilateral retinoblastoma patients. Pediatric Blood and Cancer, 2021, 68, e28882.	1.5	3
5	A phase I trial of talazoparib and irinotecan with and without temozolomide in children and young adults with recurrent or refractory solid malignancies. European Journal of Cancer, 2020, 137, 204-213.	2.8	39
6	The Art and Science of Selecting a CD123-Specific Chimeric Antigen Receptor for Clinical Testing. Molecular Therapy - Methods and Clinical Development, 2020, 18, 571-581.	4.1	13
7	Longitudinal NK cell kinetics and cytotoxicity in children with neuroblastoma enrolled in a clinical phase II trial. , 2020, 8, e000176.		14
8	A phase 1 trial of everolimus and bevacizumab in children with recurrent solid tumors. Cancer, 2020, 126, 1749-1757.	4.1	10
9	Clinical impact of postâ€induction resolution of pulmonary lesions in metastatic Ewing sarcoma. Pediatric Blood and Cancer, 2020, 67, e28150.	1.5	0
10	Predictors of narcolepsy and hypersomnia due to medical disorder in pediatric craniopharyngioma. Journal of Neuro-Oncology, 2020, 148, 307-316.	2.9	23
11	OSTPDL1: A phase II study of avelumab, a monoclonal antibody targeting programmed death-ligand 1 (PD-L1) in adolescent and young adult patients with recurrent or progressive osteosarcoma Journal of Clinical Oncology, 2020, 38, 10521-10521.	1.6	6
12	A Phase II Trial of Hu14.18K322A in Combination with Induction Chemotherapy in Children with Newly Diagnosed High-Risk Neuroblastoma. Clinical Cancer Research, 2019, 25, 6320-6328.	7.0	61
13	Reducing Compassion Fatigue in Inpatient Pediatric Oncology Nurses. , 2019, 46, 338-347.		16
14	Speaking genomics to parents offered germline testing for cancer predisposition: Use of a 2â€visit consent model. Cancer, 2019, 125, 2455-2464.	4.1	29
15	0817 Predictors of Hypersomnia and Narcolepsy in Pediatric Craniopharyngioma. Sleep, 2019, 42, A327-A328.	1.1	0
16	Are we meeting the informational needs of cancer patients and families? Perception of physician communication in pediatric oncology. Cancer, 2019, 125, 1518-1526.	4.1	28
17	Sensitivity and Specificity of the Modified Epworth Sleepiness Scale in Children With Craniopharyngioma. Journal of Clinical Sleep Medicine, 2019, 15, 1487-1493.	2.6	13
18	Comparison of Resting Energy Expenditure Assessment in Pediatric Oncology Patients. Nutrition in Clinical Practice, 2018, 33, 224-231.	2.4	2

#	Article	IF	CITATIONS
19	Predictors of Late Palliative Care Referral in Children With Cancer. Journal of Pain and Symptom Management, 2018, 55, 1550-1556.	1.2	36
20	Evaluation of a feverâ€management algorithm in a pediatric cancer center in a lowâ€resource setting. Pediatric Blood and Cancer, 2018, 65, e26790.	1.5	9
21	Clinical Characteristics of Intravenous PEG-Asparaginase Hypersensitivity Reactions in Patients Undergoing Treatment for Acute Lymphoblastic Leukemia. Journal of Pediatric Oncology Nursing, 2018, 35, 103-109.	1.5	13
22	Illness and endâ€ofâ€life experiences of children with cancer who receive palliative care. Pediatric Blood and Cancer, 2018, 65, e26895.	1.5	53
23	Prevalence, risk factors, and response to treatment for hypersomnia of central origin in survivors of childhood brain tumors. Journal of Neuro-Oncology, 2018, 136, 379-384.	2.9	18
24	Treatment intensity and symptom burden in hospitalized adolescent and young adult hematopoietic cell transplant recipients at the end of life. Bone Marrow Transplantation, 2018, 53, 84-90.	2.4	26
25	Predictors of Location of Death for Children with Cancer Enrolled on a Palliative Care Service. Oncologist, 2018, 23, 1525-1532.	3.7	27
26	Clinical Characteristics of Children and Adolescents Undergoing Hematopoietic Cell Transplantation Who Develop Oral Mucositis. Oncology Nursing Forum, 2018, 45, 457-462.	1.2	5
27	Incorporating Bereaved Parents as Faculty Facilitators and Educators in Teaching Principles of Palliative and End-of-Life Care. American Journal of Hospice and Palliative Medicine, 2018, 35, 1518-1525.	1.4	13
28	Rapid decrease of serum alpha-fetoprotein and tumor volume predicts outcome in children with hepatoblastoma treated with neoadjuvant chemotherapy. International Journal of Clinical Oncology, 2018, 23, 900-907.	2.2	10
29	Palliative Care Involvement Is Associated with Less Intensive End-of-Life Care in Adolescent and Young Adult Oncology Patients. Journal of Palliative Medicine, 2017, 20, 509-516.	1.1	94
30	Patients' and Parents' Needs, Attitudes, and Perceptions About Early Palliative Care Integration in Pediatric Oncology. JAMA Oncology, 2017, 3, 1214.	7.1	146
31	Measurable Supratentorial White Matter Volume Changes in Patients with Diffuse Intrinsic Pontine Glioma Treated with an Anti-Vascular Endothelial Growth Factor Agent, Steroids, and Radiation. American Journal of Neuroradiology, 2017, 38, 1235-1241.	2.4	7
32	Integrating nextâ€generation sequencing into pediatric oncology practice: An assessment of physician confidence and understanding of clinical genomics. Cancer, 2017, 123, 2352-2359.	4.1	58
33	Nonrhabdomyosarcoma soft tissue sarcoma <scp>(NRSTS)</scp> in pediatric and young adult patients: Results from a prospective study using limitedâ€margin radiotherapy. Cancer, 2017, 123, 4419-4429.	4.1	15
34	The Effectiveness of Trivalent Inactivated Influenza Vaccine in Children with Acute Leukemia. Journal of Pediatrics, 2017, 191, 218-224.e1.	1.8	10
35	Going straight to the source: A pilot study of bereaved parentâ€facilitated communication training for pediatric subspecialty fellows. Pediatric Blood and Cancer, 2017, 64, 156-162.	1.5	21
36	The bereavement experience of adolescents and early young adults with cancer: Peer and parental loss due to death is associated with increased risk of adverse psychological outcomes. PLoS ONE, 2017, 12, e0181024.	2.5	11

#	Article	IF	CITATIONS
37	Feasibility of Pegylated Interferon in Children and Young Adults With Resected Highâ€Risk Melanoma. Pediatric Blood and Cancer, 2016, 63, 1207-1213.	1.5	20
38	Play-based procedural preparation and support intervention for cranial radiation. Supportive Care in Cancer, 2016, 24, 2421-2427.	2.2	42
39	Children with minimal chance for cure: parent proxy of the child's health-related quality of life and the effect on parental physical and mental health during treatment. Journal of Neuro-Oncology, 2016, 129, 373-381.	2.9	23
40	Patientâ€controlled analgesia at the end of life at a pediatric oncology institution. Pediatric Blood and Cancer, 2015, 62, 1237-1244.	1.5	23
41	Adolescents' preferences for treatment decisional involvement during their cancer. Cancer, 2015, 121, 4416-4424.	4.1	87
42	Ethical Decision Making About End-of-life Care Issues by Pediatric Oncologists in Economically Diverse Settings. Journal of Pediatric Hematology/Oncology, 2015, 37, 257-263.	0.6	7
43	Tetanus toxoid and CCL3 improve dendritic cell vaccines in mice and glioblastoma patients. Nature, 2015, 519, 366-369.	27.8	429
44	Patterns of End-of-Life Care in Children With Advanced Solid Tumor Malignancies Enrolled on a Palliative Care Service. Journal of Pain and Symptom Management, 2015, 50, 305-312.	1.2	78
45	Impact of health-related quality of life and fatigue on survival of recurrent high-grade glioma patients. Journal of Neuro-Oncology, 2014, 120, 499-506.	2.9	50
46	Safety and efficacy of aerobic training in operable breast cancer patients receiving neoadjuvant chemotherapy: A phase II randomized trial. Acta Oncológica, 2014, 53, 65-74.	1.8	149
47	A novel, reproducible, and objective method for volumetric magnetic resonance imaging assessment of enhancing glioblastoma. Journal of Neurosurgery, 2014, 121, 536-542.	1.6	28
48	Phase II trial of upfront bevacizumab and temozolomide for unresectable or multifocal glioblastoma. Cancer Medicine, 2013, 2, 185-195.	2.8	36
49	Bevacizumab continuation beyond initial bevacizumab progression among recurrent glioblastoma patients. British Journal of Cancer, 2012, 107, 1481-1487.	6.4	83
50	Unmet spiritual care needs impact emotional and spiritual well-being in advanced cancer patients. Supportive Care in Cancer, 2012, 20, 2269-2276.	2.2	213
51	Assessment of the Psychometric Properties of an English Version of the Cancer Dyspnea Scale in People With Advanced Lung Cancer. Journal of Pain and Symptom Management, 2012, 44, 741-749.	1.2	17
52	Prognostic significance of functional capacity and exercise behavior in patients with metastatic non-small cell lung cancer. Lung Cancer, 2012, 76, 248-252.	2.0	173
53	A Pilot Study of IL-2Rα Blockade during Lymphopenia Depletes Regulatory T-cells and Correlates with Enhanced Immunity in Patients with Glioblastoma. PLoS ONE, 2012, 7, e31046.	2.5	98
54	Phase II study of Gleevec plus hydroxyurea in adults with progressive or recurrent lowâ€grade glioma. Cancer, 2012, 118, 4759-4767.	4.1	26

#	Article	IF	CITATIONS
55	Phase 1 trial of dasatinib plus erlotinib in adults with recurrent malignant glioma. Journal of Neuro-Oncology, 2012, 108, 499-506.	2.9	41
56	Bevacizumab and daily temozolomide for recurrent glioblastoma. Cancer, 2012, 118, 1302-1312.	4.1	132
57	Phase II study of Gleevec® plus hydroxyurea (HU) in adults with progressive or recurrent meningioma. Journal of Neuro-Oncology, 2012, 106, 409-415.	2.9	78
58	Outcome after bevacizumab clinical trial therapy among recurrent grade III malignant glioma patients. Journal of Neuro-Oncology, 2012, 107, 213-221.	2.9	24
59	A phase I trial of the farnesyl transferase inhibitor, SCH 66336, with temozolomide for patients with malignant glioma. Journal of Neuro-Oncology, 2011, 105, 601-606.	2.9	20
60	Phase I study of sunitinib and irinotecan for patients with recurrent malignant glioma. Journal of Neuro-Oncology, 2011, 105, 621-627.	2.9	62
61	Correlates of quality of lifeâ€related outcomes in breast cancer patients participating in the Pathfinders pilot study. Psycho-Oncology, 2011, 20, 559-564.	2.3	32
62	Phase 2 study of carboplatin, irinotecan, and bevacizumab for recurrent glioblastoma after progression on bevacizumab therapy. Cancer, 2011, 117, 5351-5358.	4.1	80
63	Greater chemotherapy-induced lymphopenia enhances tumor-specific immune responses that eliminate EGFRvIII-expressing tumor cells in patients with glioblastoma. Neuro-Oncology, 2011, 13, 324-333.	1.2	306
64	Exercise Behavior, Functional Capacity, and Survival in Adults With Malignant Recurrent Glioma. Journal of Clinical Oncology, 2011, 29, 2918-2923.	1.6	107
65	Phase 2 pilot study of Pathfinders: a psychosocial intervention for cancer patients. Supportive Care in Cancer, 2010, 18, 893-898.	2.2	27
66	Validation of the Patient Care Monitor (Version 2.0): A Review of System Assessment Instrument for Cancer Patients. Journal of Pain and Symptom Management, 2010, 40, 545-558.	1.2	92
67	Informational needs assessment of nonâ€Hodgkin lymphoma survivors and their physicians. American Journal of Hematology, 2010, 85, 528-532.	4.1	17
68	Poor drug distribution as a possible explanation for the results of the PRECISE trial. Journal of Neurosurgery, 2010, 113, 301-309.	1.6	219
69	Quality management of potential chemotherapy-induced neutropenic complications: evaluation of practice in an academic medical center. Supportive Care in Cancer, 2009, 17, 735-744.	2.2	3
70	Prognostic Value of Fluorine-18 Fluorodeoxyglucose Positron Emission Tomography Imaging in Patients With Advanced-Stage Non–Small-Cell Lung Carcinoma. Journal of Clinical Oncology, 2008, 26, 1459-1464.	1.6	119
71	Vitamin D Receptor and p21/WAF1 Are Targets of Genistein and 1,25-Dihydroxyvitamin D3 in Human Prostate Cancer Cells. Cancer Research, 2004, 64, 2143-2147.	0.9	60